More than ever, its management demands a multidisciplinary approach, not only to ensure effective treatment but also to prevent long-term complications and support overall quality of life [16]
The proportion of patients using basal insulin decreased from 64.7% at baseline to 55.4% at EOS ( p = 0.008)
It is only prescribed for weight loss off-label (meaning when a medication is legally and safely prescribed to treat a condition other than that for which its licenced.) Wegovy is a medication made by the same manufacturer using the same active ingredient (semaglutide) as Ozempic, but its licenced in the UK for weight loss treatment, and is therefore easier to receive a prescription for
Despite its effectiveness, potential risks are associated with semaglutide usage that cannot be overlooked
Semaglutide, known under the brands Wegovy and Ozempic, offers dual benefits in diabetes and weight management, aligning with our holistic approach to wellness